Why Is My Insurance Forcing Me to Switch to a Biosimilar? A Chicago Rheumatologist Explains

If you take a biologic medication for an autoimmune condition like rheumatoid arthritis, psoriatic arthritis, or inflammatory bowel disease, you may have received a letter from your insurance company telling you that you need to switch to a “biosimilar” version of your drug.

For many patients, this news is confusing and even a little scary. If your current treatment is working well, why would you need to change it?

As a Chicago rheumatologist and regenerative medicine physician, I want to walk you through what biologics and biosimilars actually are, whether switching is safe, and, just as importantly, the questions you have every right to ask before you agree to change your treatment plan.

What Are Biologic Medications?

Biologic drugs are different from the pills most people are used to taking. Instead of being manufactured from simple chemical compounds, biologics are grown inside living cells, such as bacteria, yeast, or animal cells.

Because they come from living sources, biologics tend to be:

• Large, complex proteins (similar in structure to antibodies or insulin)
• Used to treat serious conditions like inflammatory arthritis, cancer, and inflammatory bowel disease
• Given as an injection or an IV infusion rather than swallowed as a pill
• Expensive to produce and prescribe

One important detail: because living cells naturally vary a bit from batch to batch, no two batches of a biologic drug are ever perfectly identical — even under the same brand name.

What Is a Biosimilar?

A biosimilar is a highly similar copy of a brand-name biologic. It is not the same as a “generic” pill.

Generic pills are exact chemical copies of the original drug. Biosimilars can’t be copied that precisely because biologics are too large and complex. Instead, drug manufacturers must prove to regulators that their biosimilar:

• Closely matches the original biologic
• Works just as safely
• Works just as effectively
• Is typically offered at a lower cost

Is It Safe to Switch From a Biologic to a Biosimilar?

Generally speaking, yes. Multiple studies have shown that biosimilars are comparable to their brand-name counterparts in terms of both safety and effectiveness for autoimmune conditions.

Because of this data, more insurance companies are now requiring patients to switch to a biosimilar when one becomes available — often citing safety, efficacy, and cost savings as the reasons.

The Physician’s Counterpoint: “If It Isn’t Broken, Why Fix It?”

Here’s where things get more complicated in real-world practice.

As a physician who prescribes both biologics and biosimilars for autoimmune patients every day, I’ll be honest: I’m not always thrilled when insurance forces a switch.

Here’s why:

1. “Comparable” Doesn’t Always Mean Identical for Every Patient

Clinical studies show comparability between biologics and biosimilars on average. But in real-world practice, not every patient has a smooth, one-to-one transition when switching medications. Some patients do great. Others notice a difference in how they feel or how well their symptoms are controlled.

2. If You’re Doing Well, There Should Be a Strong Reason to Change

If a patient is stable and responding well to their current biologic, disrupting that treatment should require a genuinely important reason — ideally a medical one. In most insurance-driven switches, there isn’t a medical reason at all. The push is financial.

3. The Cost Savings May Not Be as Big as You Think

This is the part patients are rarely told: when you compare the actual cost of biologics versus biosimilars — especially on the infusion side — the price difference is often smaller than expected. Market pressures tend to bring the two closer together in price over time.

Questions You Should Ask Your Insurance Company

If your insurance is requiring you to switch to a biosimilar, you have the right to ask questions before agreeing. Consider asking:

• What is the actual cost savings created by this switch?
• Are those savings being passed on to me as the patient, or are they primarily improving the insurance company’s margins?
• Is this switch based on a medical reason, or purely a cost decision?
• What happens if I don’t respond well to the biosimilar — can I switch back?

You are the client. You deserve transparency about decisions that affect your treatment and your health.

The Bottom Line for Patients

Biosimilars are an important, generally safe advancement in autoimmune treatment, and for many patients, they work exactly as well as the original biologic. But “safe on average” is not the same as “guaranteed to work identically for you.”

If your insurance is pressuring you to switch:

• Don’t panic — but don’t stay silent either.
• Ask direct questions about cost and medical necessity.
• Advocate for your treatment history and your response to your current medication.
• Work closely with your rheumatologist to monitor how you respond if a switch is required.

Your health decisions should be about your safety and quality of life — not just an insurance company’s bottom line.

Get Expert Guidance From a Chicago Rheumatology Specialist

Navigating biologic and biosimilar treatment decisions can be overwhelming, especially when insurance companies are involved. At Chicago Arthritis, our team specializes in rheumatology, arthritis care, and regenerative medicine, and we’re committed to helping patients make informed, confident decisions about their autoimmune treatment.

Have questions about your biologic or biosimilar treatment plan? Visit ChicagoArthritis.com to learn more or schedule a consultation with our team today.

---

What Are Biologic Medications in Rheumatology? How They Work & When You Need Them

Methotrexate for Rheumatoid Arthritis: Dosage, Effects, and When to Switch to Biologics

Making Smart Medical Decisions in Rheumatoid Arthritis Care